| Texto completo | |
| Autor(es): |
Yukuyama, Megumi Nishitani
;
Zuo, Jieyu
;
Park, Chulhun
;
Yousef, Malaz
;
Bazan Henostroza, Mirla Anali
;
Barros de Araujo, Gabriel Lima
;
Bou-Chacra, Nadia Araci
;
Lobenberg, Raimar
Número total de Autores: 8
|
| Tipo de documento: | Artigo Científico |
| Fonte: | International Journal of Pharmaceutics; v. 632, p. 9-pg., 2023-01-06. |
| Resumo | |
Dissolution testing is important in assessing the in vitro drug release performance for oral administration dosage forms. However, currently, a simple and efficient in vitro test to investigate critical factors that may impact the drug release and bioavailability at the development stage of a drug-loaded nanoemulsion (NE) is lacking. Thus, in this study, we developed a new combined biphasic and modified cylinder (BP + MC) method to evaluate the dissolution profile of NEs. Flubendazole (FLZ), a Biopharmaceutical Classification System (BCS) Class II drug, offers a new prospective for drug repositioning for treating lung cancer and cryptococcal meningitis. We compared the drug release profiles of three different FLZ formulations (micronized as a suspension, loaded in NE, and solubilized in oil) by using three different methods (dialysis bag, modified cylinder method, and a new BP + MC method). The results showed potential higher drug release of FLZ from the suspension compared to FLZ-loaded NE at pH 1.2, and higher drug release from FLZ-loaded NE compared to other forms in octanol phase. These results correlate well with the in vivo test performed in mice carried out in our previous works. Further-more, the partition mechanism of the drug released from the NE is discussed in-depth in this article, as well as the advantage of drug-loaded NEs over other preparations in creating supersaturable conditions. Based on the re-sults, we provide new insights into how dissolution methods for a poorly water-solubility drug can be designed. Therefore, we present this new combined BP + MC method as a potential new discriminative dissolution test for future studies when developing drug-loaded NE and comparing with other dosage forms. (AU) | |
| Processo FAPESP: | 18/22713-2 - Estudo do reposicionamento do flubendazol para o tratamento de câncer de pulmão e meningoencefalite empregando nanossistema lipídico oral |
| Beneficiário: | Megumi Nishitani Yukuyama |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |
| Processo FAPESP: | 20/15981-0 - Estudo do reposicionamento do flubendazol para o tratamento de câncer de pulmão e meningoencefalite empregando nanossistema lipídico oral |
| Beneficiário: | Megumi Nishitani Yukuyama |
| Modalidade de apoio: | Bolsas no Exterior - Estágio de Pesquisa - Doutorado |
| Processo FAPESP: | 19/04998-2 - Formulações nanocristalinas e dispersões sólidas amorfas para a melhoria de terapias antitumorais |
| Beneficiário: | Gabriel Lima Barros de Araujo |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 17/08332-3 - Sistemas nanoestruturados com potencial aplicação no tratamento de doenças negligenciadas |
| Beneficiário: | Nádia Araci Bou-Chacra |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |